← Leaderboards
Lawrence J Zana
Consegna Pharma, Inc.
$2,872,488
Attributed
$2,872,488
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,872,488 · 2
By mechanism
R44$2,545,988 · 1
R43$326,500 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Manufacturing Scale-Up”
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Li Liang · University Of California-Irvine$7,511,446
- David Burkhart · Inimmune Corporation$5,907,864
- John Paderi John Paderi John Paderi · Ihp Therapeutics, Inc.$3,571,151
- Laurene Wang · Aimmax Therapeutics, Inc.$3,356,811
- Bozena Korczak · Vascular Vision Pharmaceuticals Company$3,058,782
Research focus
Manufacturing Scale-UpProgramsFutureManufactureParticlePre-Investigational New Drug MeetingDrug Delivery SystemsFormulationInnovationLegal PatentOpioidOverdoseDesignPharmaceutical PreparationsCommercializationDoseDrug KineticsEncapsulatedAmericanHospitalsInvestigational DrugsIn VivoMedicalSales
Grant awards (4)
IND-enabling development of a long-duration antagonist to treat opioid overdose$377,843
R44 · FY2025 · DA · contact PI
IND-enabling development of a long-duration antagonist to treat opioid overdose$837,364
R44 · FY2024 · DA · contact PI
IND-enabling development of a long-duration antagonist to treat opioid overdose$1,330,781
R44 · FY2023 · DA · contact PI
Long-acting injectable ketamine for improved substance use disorder (SUD) treatment without dissociative effects.$326,500
R43 · FY2023 · DA · contact PI